Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03797495Recruiting

Study of Individuals Affected With Hypoplasminogenemia

Role: lead

NCT05317806Phase 4Active Not Recruiting

Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency

Role: lead

NCT03921294Phase 4Terminated

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

Role: lead

NCT04567511Phase 4Recruiting

Hemlibra in Mild Hemophilia A

Role: lead

NCT02502409Unknown

Natural History Study of Factor IX Treatment and Complications

Role: collaborator

NCT03265171Unknown

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Role: collaborator

All 6 trials loaded